Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study

被引：0

作者：

Orbai, Ana-Maria ^{[1
]}

Gellett, Amanda M. ^{[2
]}

Kerr, Lisa ^{[2
]}

Constantin, Arnaud ^{[3
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[2] Eli Lilly & Co, Indianapolis, IN 46285 USA

[3] Hop Pierre Paul Riquet, Toulouse, France

来源：

ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2559

引用

页数：3

共 50 条

[1] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Rahman, Proton
Orbai, Ana-Marie
Gellett, Amanda
Kerr, Lisa
Constantin, Arnaud
Gladman, Dafna
JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 847 - 848
[2] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
Gratacos, Jordi
Turkiewicz, Anthony
Dokoupilova, Eva
Gellett, Amanda
Sprabery, Aubrey
Geneus, Vladimir
Constantin, Arnaud
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[3] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Genovese, Mark C.
Combe, Bernard
Kremer, Joel
Adams, David
Lee, Chin
Kerr, Lisa
Nash, Peter
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[4] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Genovese, M. C.
Combe, B.
Kremer, J.
Adams, D. H.
Lee, C.
Kerr, L.
Nash, P.
Garcia, E. G.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S158 - S158
[5] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Genovese, M. G.
Combe, B.
Kremer, J.
Adams, D.
Lee', C.
Kerr, L.
Nash, P.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1035 - 1036
[6] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study
Genovese, Mark
Helliwell, Philip
Combe, Bernard
Kremer, Joel
Adams, David
Lee, Chin
Kerr, Lisa
Nash, Peter
Rahman, Proton
JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 996 - 996
[7] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
Ana-Maria Orbai
Jordi Gratacós
Anthony Turkiewicz
Stephen Hall
Eva Dokoupilova
Bernard Combe
Peter Nash
Gaia Gallo
Clinton C. Bertram
Amanda M. Gellett
Aubrey Trevelin Sprabery
Julie Birt
Lisa Macpherson
Vladimir J. Geneus
Arnaud Constantin
Rheumatology and Therapy, 2021, 8 : 199 - 217
[8] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
Orbai, Ana-Maria
Gratacos, Jordi
Turkiewicz, Anthony
Hall, Stephen
Dokoupilova, Eva
Combe, Bernard
Nash, Peter
Gallo, Gaia
Bertram, Clinton C.
Gellett, Amanda M.
Sprabery, Aubrey Trevelin
Birt, Julie
Macpherson, Lisa
Geneus, Vladimir J.
Constantin, Arnaud
RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 199 - 217
[9] IMPROVED PAIN AND FATIGUE WITH IXEKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR FOLLOW-UP FROM A PHASE 3 STUDY (SPIRIT-P2)
Orbai, A. M.
De Vlam, K.
Nash, P.
Birt, J.
Gallo, G.
Stenger, K.
Geneus, V.
Combe, B.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 771 - 771
[10] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)
Gratacos-Masmitja, J.
Turkiewicz, A.
Dokoupilova, E.
Gellett, A. M.
Sprabery, T.
Geneus, V. J.
Constantin, A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1154 - 1154

← 1 2 3 4 5 →